ImmunoPrecise Regains Compliance with Nasdaq Minimum Bid Price Requirement
We're building the digital infrastructure that connects biological complexity with real-world impact - enabling new possibilities in therapeutic development and beyond.
The notice, dated July 11, 2025, stated that for the 10 consecutive business days from June 26, 2025, through July 10, 2025, the closing bid price of the Company's common shares was at or above $1.00 per share. As a result, ImmunoPrecise has satisfied the requirements for continued listing on the Nasdaq Capital Market, and the matter is now closed.
'This compliance milestone reflects the growing recognition of our evolution into a platform company built around bio-native AI,' said Dr. Jennifer Bath, CEO of ImmunoPrecise. 'We're building the digital infrastructure that connects biological complexity with real-world impact - enabling new possibilities in therapeutic development and beyond. The recent momentum in our share price is a strong signal of support for that vision.'
Through its proprietary LENS ai™ platform powered by HYFT ® technology, ImmunoPrecise is reimagining how biological data can be modeled and deployed at scale. The LENS ai platform is transforming therapeutic discovery from a decades-long process to rapid, precision-guided development by systematically identifying the most promising therapeutic pathways through integration of sequence, structure, literature and functional data across the entire biosphere.
Our integrated framework enables unprecedented zero-shot discovery scenarios where LENS ai predicts therapeutic interactions for completely novel targets, demonstrated through recent validation across 17 previously unseen antibody-protein complexes, achieving near-crystallography precision without prior training data. This unique bio-native AI approach captures functional meaning rather than structural patterns, enabling new capabilities across R&D from drug and vaccine discovery to systems biology and positioning IPA at the frontier of TechBio innovation.
About ImmunoPrecise Antibodies Ltd.
ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) is advancing Bio-Native™ AI at the intersection of biology and computation. The Company's LENSai™ and HYFT ® platforms enable large-scale reasoning across sequence, structure, function, and scientific literature, powering next-generation workflows across drug discovery, diagnostics, vaccine design, and molecular systems biology.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of applicable United States and Canadian securities laws. Forward-looking statements are often identified by words such as 'expects,' 'intends,' 'plans,' 'anticipates,' 'believes,' or similar expressions, or by statements that certain actions, events, or results 'may,' 'will,' 'could,' or 'might' occur or be achieved. These statements include, but are not limited to, statements regarding the Company's strategic direction, the Company's future growth, its ability to execute on its scientific, commercial, and capital markets initiatives, and the continued evolution of its leadership and business strategy.
Forward-looking statements are based on management's current expectations, assumptions, and projections about future events. Actual results may differ materially from those expressed or implied due to a variety of factors, many of which are beyond the Company's control. These factors include, but are not limited to, changes in board or executive leadership; shifts in strategic priorities; scientific or operational challenges; evolving market and economic conditions; changes in regulatory environments; the pace of innovation in AI and biotechnology; and other risks inherent to the Company's industry and business model.
Forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to differ materially from those expressed or implied herein. Additional information regarding risks and uncertainties is included in the Company's Annual Report on Form 20-F, as amended, for the fiscal year ended April 30, 2024, available on the Company's SEDAR+ profile at www.sedarplus.ca and EDGAR profile at www.sec.gov/edgar. Should any of these risks materialize, actual results could vary significantly from those currently anticipated.
Readers are cautioned not to place undue reliance on these forward-looking statements. Except as required by applicable law, the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
7 minutes ago
- Yahoo
Moon Surgical Launches Maestro™ Platform at Lee Health
PARIS and SAN FRANCISCO, July 15, 2025 /PRNewswire/ -- Moon Surgical, the leader in Physical AI for the operating room, today announced the successful launch of its Maestro™ Platform at Lee Health's Gulf Coast Medical Center in Fort Meyers, Florida, marking another milestone in the platform's growing adoption across the United States. Lee Health has already completed over 100 procedures using Maestro, including bariatric and general surgeries. Notably, the hospital reported: Zero adverse events No increase in operative time or length of stay, even in the initial cases Operational efficiencies which enable the reduction of one surgical technologist or advanced provider per case without compromising care In just the first 25 bariatric cases, Maestro helped Lee Health save the equivalent of 8.3 full working days of surgical tech time, demonstrating its impact on staffing efficiency and resource optimization. QUOTE: Juan Ibarra, M.D - Robotic Surgery Program Manager, Lee Heath: "We're proud to be among the early U.S. institutions to adopt the Maestro Platform. We've completed over 100 procedures, each one delivering excellent clinical and operational outcomes. For surgeons who prefer traditional laparoscopy, Maestro offers a smart and reliable assistant without changing their preferred surgical approach. We are proud at Lee Health to be setting the pace with technology that improves efficiency, maintains safety, and supports our teams." "The program launch and partnership with Lee Health is a great example of how Maestro is defining a new category of MIS." said Anne Osdoit, Moon Surgical CEO. "Maestro has quickly delivered consistent and scalable positive impact for surgeons, their teams, the hospital system and its patients." The launch at Lee Health comes on the heels of a recent announcement on the rapidly broadening usage of the Maestro™ System, which has now supported over 1,600 procedures worldwide, including 1,400 in the past year alone, across 60 different types of minimally invasive surgeries. Maestro's growing adoption highlights its adaptability across specialties and its value in high-volume outpatient care. Moon Surgical continues to redefine the operating room with Maestro, a surgical technology platform powered by Physical AI. Designed to enhance human performance, Maestro supports surgical teams with adaptability, control, and efficient integration into existing workflows. About Moon Surgical Moon Surgical is transforming the operating room with Physical AI, seamlessly integrating intelligence and robotics to elevate the capabilities of surgical teams. The Maestro System represents a new category of minimally invasive surgery—expanding the scale at which robotics are delivered into the operating rooms. Instinctive, collaborative, and cost-effective, Maestro empowers teams to deliver exceptional care with greater adaptability and control. Moon Surgical. Inspiring and Innovating the Art of Surgery. Moon Surgical® and Maestro® are registered trademarks of Moon Surgical, SAS View original content to download multimedia: SOURCE Moon Surgical
Yahoo
8 minutes ago
- Yahoo
Amylyx Pharmaceuticals Shares Promising Avexitide Data for Post-Bariatric Hypoglycemia at ENDO 2025, Phase 3 Enrollment Nears Completion
Amylyx Pharmaceuticals Inc. (NASDAQ:AMLX) is one of the best low priced pharma stocks to buy now. On July 13, Amylyx Pharmaceuticals announced new exploratory analyses from its Phase 2 PREVENT and Phase 2b clinical trials of avexitide for post-bariatric hypoglycemia/PBH at the Endocrine Society's annual meeting (ENDO 2025). Avexitide is an investigational, first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist and has received FDA Breakthrough Therapy designation for PBH. PBH is a complication that can arise after bariatric surgery, such as Roux-en-Y gastric bypass. A medical scientist in a lab coat gazing at a microscopic view of a drug in development. There are currently no FDA-approved treatments for PBH. Avexitide works by binding to the GLP-1 receptor on pancreatic islet beta cells, blocking the effect of excessive GLP-1 and thus mitigating hypoglycemia by decreasing insulin secretion and stabilizing glucose levels. Avexitide has generally been well-tolerated with a favorable safety profile across all trials. Amylyx expects to complete recruitment for the LUCIDITY trial this year, with topline data anticipated in H1 2026. Amylyx Pharmaceuticals Inc. (NASDAQ:AMLX) is a clinical-stage pharmaceutical company that discovers and develops treatment options for neurodegenerative diseases and endocrine conditions in the US. While we acknowledge the potential of AMLX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
9 minutes ago
- Yahoo
Klotho Neurosciences, Inc. Granted FDA Orphan Drug Designation for KLTO-202 for Treatment of Amyotrophic Lateral Sclerosis ("ALS" or "Lou Gehrig's Disease")
NEW YORK, July 10, 2025 /PRNewswire/ -- Klotho Neurosciences, Inc. (Nasdaq: KLTO), a gene and cell therapy company focused on the treatment of neurodegenerative and other aging-related diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to the company's novel secreted-Klotho (s-KL) promoter, gene and delivery system (KLTO-202, or for the treatment of ALS. The FDA grants Orphan Drug Designation to drugs and biologics that are intended for safe and effective treatment, diagnosis or prevention of rare diseases or disorders that affect fewer than 200,000 people in the U.S. The Orphan Drug Designation provides certain incentives, such as tax credits, toward the cost of human clinical trials and a waiver for the payment of the GDUFA User Fee for market applications. Additionally, Orphan Drug Designation of the product provides the developers seven years of US market exclusivity and independent from the Company's intellectual property protection. "Receiving the Orphan Drug Designation for for the early treatment of ALS underscores the importance of bringing new treatment options to patients suffering from this rare, universally fatal disease" said Dr. Joseph Sinkule, Klotho's Chief Executive Officer. "My cousin Karen died from this horrific disease. We aim to deliver the first gene replacement therapy addressing the neurologic insult resulting in motor neuron damage and the potential neurologic protection induced by providing therapeutic blood, brain, and muscle concentrations of the s-KL protein. After the FDA's review of the data leading to the Orphan Drug Designation, we believe this ODD designation provides strong validation of our science and our approach to treat this disease" concludes Dr. Sinkule. ALS is sometimes referred to as Lou Gehrig's disease. Lou Gehrig, who played for the New York Yankees for 17 years in the 1920s and 1930s, stunned players and fans by retiring from baseball at the age of 36 after being diagnosed with ALS. Prior to this diagnosis, Gehrig played in a record-breaking 2,130 consecutive games, was referred to as the "Iron Horse," and was considered one of the greatest baseball players of all time. Less than two years later, at the age of 37, Gehrig died of complications from ALS. ALS is also referred to as Motor Neuron Disease in the UK and elsewhere. ALS is considered a rare disease and affects fewer than 200,000 people in the US, with around 5,000 new cases diagnosed each year. Klotho Neurosciences will have completed "proof of concept" studies in two animal models of human ALS and the Company is currently initiating manufacturing of the ALS-targeted product candidate, followed by meetings with the U.S. FDA and EMA in Europe to concur with the development path going forward. KLTO-202, the company's lead product candidate targeting motor neuron diseases and muscular dystrophies, is composed of a muscle-specific promoter called "desmin," driving the expression of the s-KL gene transcript and s-KL protein, with targeted delivery of the gene therapy to the neuromuscular junction - the interface between the spinal cord and the muscles. At this time, KLTO-202 is not approved for human use by any regulatory authority. About Klotho Neurosciences, Neurosciences, Inc. (NASDAQ: KLTO), is a biogenetics company focused on the development of innovative, disease-modifying cell and gene therapies using a protein derived from a patented form of the "anti-aging" human Klotho gene (s-KL), and its novel delivery systems to transform and improve the treatment of neurodegenerative and age-related disorders such as ALS, Alzheimer's, and Parkinson's disease. The Company's current portfolio consists of its proprietary cell and gene therapy programs using DNA and RNA as therapeutics and genomics-based diagnostic assays. The Company is managed by a team of individuals and advisors who are highly experienced in biopharmaceutical product development and commercialization. For more information, please visit the company's website at Investor Contact and Corporate Communications: - Jeffrey LeBlanc, CFOir@ Cautionary Note Regarding Forward-Looking StatementsThis press release contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements generally are identified by the words "believe," "project," "expect," "anticipate," "estimate," "intend," "strategy," "future," "opportunity," "plan," "may," "should," "will," "would," "will be," "will continue," "will likely result," and similar expressions. Without limiting the generality of the foregoing, the forward-looking statements in this press release include descriptions of the Company's future commercial operations. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, such as the Company's inability to implement its business plans, identify and realize additional opportunities, or meet or exceed its financial projections and changes in the regulatory or competitive environment in which the Company operates. You should carefully consider the foregoing factors and the other risks and uncertainties described in the documents filed or to be filed by the Company with the U.S. Securities and Exchange Commission (the "SEC") from time to time, which could cause actual events and results to differ materially from those contained in the forward-looking statements. Copies of these documents are available on the SEC's website, All information provided herein is as of the date of this press release, and the Company undertakes no obligation to update any forward-looking statement, except as required under applicable law. View original content to download multimedia: SOURCE Klotho Neurosciences, Inc.
